){kind=logo}
Challenge A medium-sized pharmaceutical company was preparing to add a broader indication to a product already marketed in several rare indications in the US market. Ascenian was charged with identifying access and (net) pricing challenges and developing risk mitigation strategies. Solution Ascenian’s core consulting team, which included a former high-ranking official at a top US … Continued
Challenge A large pharmaceutical company needed to develop and refine differentiated payer value communications in preparation for launch into a crowded class in a saturated category. Solution Ascenian supported the client with a multi-phase project which took four months: (1) internal stakeholder interviews to ensure all functions’ perspective were considered and incorporated, (2) development of … Continued
Challenge A large pharmaceutical company with a digital health technology sought an evidence planning framework to support evidence needs of dual key stakeholders: national European HTA agencies and regional European budget holders. Solution In four working sessions with the client, a cross-competency Ascenian team – comprised of HTA methodology experts, funding specialists from sick funds, … Continued
Challenge A mid-size US-headquartered biotech with a molecule in an orphan indication in Phase 2 sought EU HTA input to Phase 3 design and guidance on HTA submission with a conditional marketing authorisation. Focus areas were level of data uncertainty, validation needs and post-launch evidence requirements. Solution Ascenian worked across the client’s functional areas teams … Continued
